H
Henk J. Out
Researcher at Radboud University Nijmegen
Publications - 38
Citations - 1887
Henk J. Out is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Follicle-stimulating hormone & Gonadotropin. The author has an hindex of 23, co-authored 38 publications receiving 1837 citations. Previous affiliations of Henk J. Out include Utrecht University & Organon International.
Papers
More filters
Journal ArticleDOI
Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies.
TL;DR: It is concluded that thrombosis or infarctions are prominent features in placenta from patients with anti-phospholipid antibodies and intra-uterine fetal death and antithrombotic treatment during pregnancy forms a rational approach in these patients.
Journal ArticleDOI
A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization
TL;DR: Recombinant FSH (Puregon) is more effective than urinary FSH in inducing multifollicular development and achieving an ongoing pregnancy in infertile women undergoing in-vitro fertilization.
Journal ArticleDOI
A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies.
Henk J. Out,Hein W. Bruinse,Godelieve C.M.L. Christiaens,Marja van Vliet,Philip G. de Groot,H. Karel Nieuwenhuis,Ronald H. W. M. Derksen +6 more
TL;DR: The presence of antiphospholipid antibodies is a risk factor for adverse pregnancy outcome and a low birth weight could be predicted by the presence of anticardiolipin antibodies in live born infants.
Journal ArticleDOI
Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation
Henk J. Out,Didi D.M. Braat,Bea A.M.E. Lintsen,Timur Gurgan,Orhan Bukulmez,Oya Gökmen,Gurhan Keles,Pedro Caballero,José M. González,Francisco Fábregues,Juan Balasch,Roger Roulier +11 more
TL;DR: It is concluded that in women between 30 and 39 years of age, the decline in number of oocytes retrieved with increasing age cannot be overcome by augmenting the daily dose of recombinant FSH from 150 to 250 IU.
Journal ArticleDOI
Recombinant Follicle-Stimulating Hormone (Follitropin Beta, Puregon) Yields Higher Pregnancy Rates in In Vitro Fertilization than Urinary Gonadotropins
TL;DR: Follitropin beta (Puregon) used for controlled ovarian hyperstimulation in IVF yields significantly higher PRs compared with urinary gonadotropins.